In this issue:
Fifteen-year prostate cancer outcomes after monitoring, surgery, or radiotherapy
Androgen receptor proteolysis targeting chimeras
Nomogram of outcomes for PSMA-PET-based salvage radiotherapy
Abiraterone + enzalutamide for metastatic prostate cancer
Intraoperative fluorescence imaging of PSMA-positive prostate cancer
PSA level at salvage radiotherapy and risk of death
MRI and biomarkers for diagnosis in high genetic prostate cancer risk
Prior local therapy and response to androgen receptor axis-targeted therapy in mCRPC
Outcomes of germline BRCA2 mutation carriers
Preoperative endogenous total testosterone and prostate cancer progression
Please login below to download this issue (PDF)